Pozen (POZN) resumes trading -18.1% AH after the FDA said the company's Phase 1 study failed to...

|By:, SA News Editor

Pozen (POZN) resumes trading -18.1% AH after the FDA said the company's Phase 1 study failed to demonstrate the bioequivalence of PA32540 to enteric-coated aspirin 325 mg using acetylsalicylic acid as the analyte, and further study will be needed.